|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury显示文摘Neglected for years, astrocytes are now recognized to fulfill and support many, if not all, homeostatic functionsof the healthy central nervous system(CNS). During neurodegenerative diseases such as amyotrophic lateral sclerosis(ALS) and spinal cord injury(SCI), astrocytes in the vicinity of degenerating areas undergo both morphological and functional changes that might compromise their intrinsic properties. Evidence from human and animal studies show that deficient astrocyte functions or loss-of-astrocytes largely contribute to increased susceptibility to cell death for neurons, oligodendrocytes and axons during ALS and SCI disease progression. Despite exciting advances in experimental CNS repair, most of current approaches that are translated into clinical trials focus on the replacement or support of spinal neurons through stem cell transplantation, while none focus on the specific replacement of astroglial populations. Knowing the important functions carried out by astrocytes in the CNS, astrocyte replacement-based therapies might be a promising approach to alleviate overall astrocyte dysfunction, deliver neurotrophic support to degenerating spinal tissue and stimulate endogenous CNS repair abilities. Enclosed in this review, we gathered experimental evidence that argue in favor of astrocyte transplantation during ALS and SCI. Based on their intrinsic properties and according to the cell type transplanted, astrocyte precursors or stem cell-derived astrocytes promote axonal growth, support mechanisms and cells involved in myelination, are able to modulate the host immune response, deliver neurotrophic factors and provide protective molecules against oxidative or excitotoxic insults, amongst many possible benefits. Embryonic or adult stem cells can even be genetically engineered in order to deliver missing gene products and therefore maximize the chance of neuroprotection and functional recovery. However, before broad clinical translation, further preclinical data on safety, reliability and therapeutic efficiency should be collected. Although several technical challenges need to be overcome, we discuss the major hurdles that have already been met or solved by targeting the astrocyte populationin experimental ALS and SCI models and we discuss avenues for future directions based on latest molecular findings regarding astrocyte biology. | Charles Nicaise Dinko Mitrecic Aditi Falnikar Angelo C Lepore | 2015 | World Journal of Stem Cells2015，7，2： | 13 |
| 2 | Influence of proton pump inhibitors in the development of spontaneous bacterial peritonitis显示文摘AIM To investigate whether the use of proton pump inhibitors(PPIs) increases the incidence of spontaneous bacterial peritonitis(SBP) in patients with cirrhosis and ascites.METHODS An historical cohort study was carried out in cirrhotic outpatients with ascites followed in a specialized clinic at a tertiary hospital in Southern Brazil. Patient charts were reviewed to collect information on the variables of interest as the use of PPIs. Primary outcome was defined as development of SBP during the study period. SBP was diagnosed based on ascitic fluid polymorphonuclear cell count ≥ 250 cells/mm3 without evidence of an intraabdominal, surgically treatable source of infection.RESULTS Of 738 cirrhotic patients, 582(58.2% male) were enrolled, with mean age of 53.6 ± 12 years. Hepatitis C virus infection(36.2%) and alcohol abuse(25.6%) were the main etiologies of cirrhosis. The presence of ascites was detected in 299(51.4%) patients during the development of the study. Nineteen patients with previous diagnosis of SBP undergoing secondary prophylaxis and 22 patients with insufficient PPI data were further excluded. Of 258 patients with ascites, 151 used PPIs, and 34 developed SBP(22.5%). Among 107 non-users of PPIs, 23 developed SBP(21.5%)(HR = 1.44, 95%CI: 0.85-2.47, P = 0.176). The median follow-up time of patients using PPI was 27 mo vs 32 mo for non-users. Univariate analysis of the risk factors associated with the development of SBP revealed a significant association of SPB with the severity of liver disease according to the Child-Turcotte-Pugh(CTP) score. Multivariate analysis confirmed that CTP score was the only independent variable influencing the occurrence of SBP. Survival at 60 mo(Kaplan-Meier analysis) was similar in users and non-users of PPI, independently of the presence of SBP(58.4% vs 62.7% respectively, P = 0.66). For patients with SBP, survival at 60 mo was 55.1%, vs 61.7% in patients without SBP(P = 0.34). CONCLUSION In conclusion, the rate of SBP was not significantly different in users or non-users of PPIs in this cohort of cirrhotic with ascites. | Suelen A S Miozzo Jorge A John Marcelo C Appel-da-Silva Isabella A Dossin Cristiane V Tovo Angelo A Mattos | 2017 | World Journal of Hepatology2017，9，35： | 5 |
| 3 | Essential role of TRPC1 channels in cardiomyoblasts hypertrophy mediated by 5-HT 2A serotonin receptors显示文摘 | Cécile Vindis Romina D’Angelo Elodie Mucher Anne Nègre-Salvayre Angelo Parini Jeanne Mialet-Perez | 2009 | Biochemical and Biophysical Research Communications2009，，1： | 2 |
| 4 | Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle显示文摘 | D'ANGELO J G BORD N C POSNER GH | 2009 | J Antimicrob Chemother2009，63，1： | 1 |
| 5 | Systematic investigation of monolithic bipolar transistors irradiated with neutrons, heavy ions and electrons for space application 显示文摘 | CONSOLANDI C ANGELO P D FALLICA G | 2006 | Nucl Instr and Meth In Phys Res B2006，252，2： | 1 |
| 6 | Assessing Public-privateResearch Collaboration:is it Possible to Compare University Per-formance显示文摘 | Abramo G D'Angelo C A Solazzi M | 2010 | Scientometrics2010，84，1： | 1 |
| 7 | Deep dephosphorization treatments for steel显示文摘 | Borgianni C Angelo R D | 1991 | Ctajib1991，3，： | 1 |
| 8 | Vascular endothelial growth factors and angiogenesis显示文摘 | Frelin C Ladoux A D'angelo G | | 0，，： | 1 |
| 9 | Thymosin alpha1: the regulator of regu-lators 显示文摘 | Pierluigi B D'Angelo C FallarinoF | 2010 | Ann N Y Acad Sci2010，1194，： | 1 |
| 10 | Towards gene therapy for deafness显示文摘 | Di Domenico M Ricciardi C Martone T Mazzarella N. Cassandro C. Chiarella G. D'Angelo L. Cassandro E | | 0，，： | 1 |
| 11 | Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions:implications with neuronal vulnerability in Huntington's disease显示文摘 | Giampà C DeMarch Z D'Angelo V | 2006 | Eur J Neurosci2006，23，8： | 1 |
| 12 | Analysis of Lipids from Cooked Beef by Thin-layerChromatography with Flame-ionization Detection显示文摘 | St Angelo A J James Jr C | 1993 | JAOCS1993，70，12： | 1 |
| 13 | Treatment of landfill leachate by reverse osmosis显示文摘 | Angelo C Rolando R Nicola V | 1999 | Water Research1999，33，3： | 1 |
| 14 | Distributed simulation of modular time Petri nets: an approach and a case study exploiting temporal uncertainty显示文摘 | Franco C Angelo F Libero N | 2007 | Real-time System2007，35，1： | 1 |
| 15 | Tollip is a mediator of protein sumoylation显示文摘 | Ciarrocchi A D Angelo R Cordiglieri C | 2009 | PLoS One2009，4，2： | 1 |
| 16 | The molecular pathogenesis of small cell lung cancer显示文摘 | D' Angelo S P Pietanza M C | 2010 | Zhongguo Fei Ai Za Zhi2010，13，11： | 1 |
| 17 | Preemptive analgesia for postoperative pain control:a review显示文摘 | Laura C Guglielmo C Angelo R D | 2010 | Clin Drug invest-ing2010，30，2： | 1 |
| 18 | IL-22 defines a novel immune pathway of antifungal resistance显示文摘 | De Luca A Zelante T D'Angelo C | | 0，，： | 1 |
| 19 | Identifying Interdisciplinary Through the Disciplinary Classification of Coauthors of Scientific Publications显示文摘 | Abramo G D’Angelo C A Costa F | 2012 | Journal of the American Society for Information Science and Technology2012，63，11： | 1 |
| 20 | Teaching Neurolmage: spinalextradural arachnoid cyst: a rare cause of back pain显示文摘 | De BP Lucantoni C D'Angelo L | 2008 | Neurology2008，71，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员